Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference20211006113325
Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference
October 6, 2021
FORT COLLINS, Colo., Oct. 06, 2021 — Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will participate in the Alliance Global Partners (A.G.P.) Biotech and Specialty Pharma Conference taking p...
Statera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Development Summit20211005115225
Statera Biopharma Announces CEO Mike Handley to Speak During Virtual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
October 5, 2021
FORT COLLINS, Colo., Oct. 05, 2021 — Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that Michael K. Handley, President and Chief Executive Officer, has been invited to participate as an expert speaker...
Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell20210902112514
Statera BioPharma, Inc. to Ring Nasdaq Stock Market Closing Bell
September 2, 2021
FORT COLLINS, Colo., Sept. 2, 2021 /PRNewswire/ -- Statera BioPharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that President and CEO Michael K. Handley and other members of the management team will ring the Nasdaq Closing Bel...
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement20210813193640
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
August 13, 2021
Cytocom to fund research in cancer, autoimmune and inflammatory conditions, and infectious diseases and applications to clinical-stage therapies Research to accelerate immune-modulating drug development, leveraging world-class research infrastructure and Cytocom’s proprietary AIMS™ discovery platform FORT COLLINS, Colo., Aug. 12, 2021 /PRNews...
Load more
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs20230315120201
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs
March 15, 2023
FORT COLLINS, Colo., March 15, 2023 — Statera Biopharma, Inc. (OTCPK:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration an...
Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB® Venture Marketplace20230124144833
Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB® Venture Marketplace
January 24, 2023
FORT COLLINS, CO / January 24, 2023 / Statera Biopharma, Inc. (NASDAQ:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom...
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm20220614113128
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
June 14, 2022
FORT COLLINS, Colo., June 14, 2022 — Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration a...
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products20220513113127
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
May 13, 2022
Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders FORT COLLINS, Colo., May 13, 2022 — Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company cr...
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone20220427201142
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
April 27, 2022
FORT COLLINS, Colo., April 27, 2022 — Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today ...
Load more